title: Pharmacokinetics interactions of monoclonal antibodies.
abstract: The clearance of therapeutic monoclonal antibodies (mAbs) typically does not involve cytochrome P450 (CYP450)-mediated metabolism or interaction with cell membrane transporters, therefore the pharmacokinetics interactions of mAbs and small molecule drugs are limited. However, a drug may affect the clearance of mAbs through the modulation of immune response (e.g., methotrexate reduces the clearance of infliximab, adalimumab, and golimumab, possibly due to methotrexate's inhibitory effect on the formation of antibodies against the mAbs). In addition, mAbs that are cytokine modulators may modify the metabolism of drugs through their effects on P450 enzymes expression. For example, cytokine modulators such as tocilizumab (anti-IL-6 receptor antibody) may reverse the "inhibitory" effect of IL-6 on CYP substrates, resulting in a "normalization" of CYP activities. Finally, a drug may alter the clearance of mAbs by either increasing or reducing the levels of expression of targets of mAbs on the cell surface. For instance, statins and fibrates induce PCSK9 expression and therefore increase cellular uptake and clearance of alirocumab and evolocumab, anti-PCSK9 antibodies. In the present review, we will provide an overview on the pharmacokinetics properties of mAbs as related to the most relevant examples of mAbs-small molecule drug interaction.
authors.affiliation: Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padua, Italy. Electronic address: nicola.ferri@unipd.it.
authors.forename: Nicola
authors.initials: N
authors.lastname: Ferri
authors.affiliation: Dipartimento di Oncologia e Emato-Oncologia, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Bellosta
authors.affiliation: EDRA S.p.A., Milan, Italy.
authors.forename: Ludovico
authors.initials: L
authors.lastname: Baldessin
authors.affiliation: EDRA S.p.A., Milan, Italy.
authors.forename: Donatella
authors.initials: D
authors.lastname: Boccia
authors.affiliation: Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy.
authors.forename: Giorgi
authors.initials: G
authors.lastname: Racagni
authors.affiliation: Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Corsini
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D004347:Drug Interactions; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal
keywords: Alirocumab; Evolocumab; IL-6; Methotrexate; Monoclonal antibodies; PCSK9; Reticuloendothelial system; Simvastatin; Tocilizumab